Approval is based on year one data from the Phase III KESTREL and KITE clinical trials investigating Beovu (brolucizumab-dbll) 6 mg versus aflibercept 2 mg in DME patients1,2 In KESTREL and KITE, Beovu was non-inferior to aflibercept in change…Original Article
Novartis Announces FDA Approval of Beovu for the Treatment of Diabetic Macular Edema
